A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

[1]  Hugh M. Davis,et al.  Pharmacokinetic and Pharmacodynamic Modeling of an Anti–Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma , 2010, Clinical Cancer Research.

[2]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[3]  P. Loehrer.  Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma , 2008 .

[4]  Michael L. Wang,et al.  Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. , 2007, Cancer cell.

[5]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[6]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[7]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[8]  W. Bro,et al.  Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). , 2006, The journal of supportive oncology.

[9]  R. Motzer,et al.  Targeted therapy for metastatic renal cell carcinoma , 2006, British Journal of Cancer.

[10]  O. Altundag,et al.  Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Trikha,et al.  CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice , 2004, International journal of cancer.

[12]  J. Blay,et al.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Rehak,et al.  Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. , 2003, Urology.

[15]  R. Figlin,et al.  Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. , 2003, The Journal of urology.

[16]  Yuan-Chang Chung,et al.  Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator , 2003, European journal of gastroenterology & hepatology.

[17]  P. Royston,et al.  Metastatic renal carcinoma comprehensive prognostic system , 2003, British Journal of Cancer.

[18]  J. Glaspy.  Therapeutic options in the management of renal cell carcinoma. , 2002, Seminars in oncology.

[19]  F. Mahmoud,et al.  The role of C-reactive protein as a prognostic indicator in advanced cancer , 2002, Current oncology reports.

[20]  R. Dantzer,et al.  Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy , 2001, Psychoneuroendocrinology.

[21]  K. Nakao,et al.  Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. , 2000, The Journal of clinical investigation.

[22]  P. Lissoni,et al.  Pretreatment serum markers and lymphocyte response to interleukin-2 therapy , 1999, British Journal of Cancer.

[23]  I. Rensink,et al.  Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating study , 1998, British journal of haematology.

[24]  K. Grankvist,et al.  Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. , 1997, European journal of cancer.

[25]  J. Blay,et al.  Role of interleukin‐6 in the paraneoplastic inflammatory syndrome associated with renal‐cell carcinoma , 1997, International journal of cancer.

[26]  L. Aarden,et al.  Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. , 1996, The Journal of clinical investigation.

[27]  B. Klein,et al.  Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. , 1995, Blood.

[28]  K. Kurth,et al.  Investigative Urology: Hypercalcemia and Cosecretion of Interleukin-6 and Parathyroid Hormone Related Peptide by a Human Renal Cell Carcinoma Implanted Into Nude Mice , 1995 .

[29]  M. Laakso,et al.  Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. , 1995, Blood.

[30]  K. Kurth,et al.  Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. , 1995, The Journal of urology.

[31]  B. Klein,et al.  Human anti‐mouse antibody response to the injection of murine monoclonal antibodies against IL‐6 , 1994, Clinical and experimental immunology.

[32]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.